Prot# DES.C.301: A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of Desonide Foam, 0.05% in the Treatment of Adolescent and Pediatric Subjects with Mild to Moderate Atopic Dermatitis